October 19, 2020 07:30 AM EDTUpdated October 20, 06:50 AM
Coronavirus

Covid-19 roundup: Pars­ing Bourla, a top an­a­lyst sees im­proved chances for Pfiz­er vac­cine; Fau­ci: No sur­prise that Trump was hit by Covid-19

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

John Carroll

Editor & Founder

With a med­ley of ad­verse events hob­bling the late-stage de­vel­op­ment of vac­cines and drugs, Pfiz­er CEO Al­bert Bourla’s lat­est — ex­tend­ed — time­line for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

A service from the Financial Times